Sarcopenia, the progressive loss of skeletal muscle mass and function, is an emerging and significant complication in patients with chronic liver diseases, particularly those with metabolic dysfunction-associated fatty liver disease (MAFLD) and cirrhosis. The increasing global prevalence of obesity and metabolic syndrome has led to a surge in MAFLD cases, which now affects both older and younger populations. Sarcopenia in these individuals is associated with frailty, muscle weakness, impaired physical function, and poor clinical outcomes, including prolonged hospitalizations, heightened infection risk, and increased mortality. The pathophysiological mechanisms linking sarcopenia to liver disease are multifactorial, involving insulin resistance, chronic systemic inflammation, mitochondrial dysfunction, and impaired muscle regeneration. Sarcopenia is particularly prevalent in advanced liver disease, with up to 80% of cirrhotic patients showing muscle loss, which further complicates posttransplant recovery. Early intervention with nutritional strategies, including protein supplementation, branched-chain amino acids, and vitamin D, is essential to mitigate muscle wasting. Additionally, lifestyle modifications, such as physical activity and emerging nutraceutical therapies, represent promising avenues for improving muscle mass, functional capacity, and overall prognosis in this population.